These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16923421)

  • 1. Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
    Reed SD; McMurray JJ; Velazquez EJ; Schulman KA; Califf RM; Kober L; Maggioni AP; Van de Werf F; White HD; Diaz R; Mareev V; Murin J;
    Am Heart J; 2006 Sep; 152(3):500-8. PubMed ID: 16923421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
    Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
    Aguilar D; Solomon SD; Køber L; Rouleau JL; Skali H; McMurray JJ; Francis GS; Henis M; O'Connor CM; Diaz R; Belenkov YN; Varshavsky S; Leimberger JD; Velazquez EJ; Califf RM; Pfeffer MA
    Circulation; 2004 Sep; 110(12):1572-8. PubMed ID: 15364810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
    Solomon SD; Skali H; Anavekar NS; Bourgoun M; Barvik S; Ghali JK; Warnica JW; Khrakovskaya M; Arnold JM; Schwartz Y; Velazquez EJ; Califf RM; McMurray JV; Pfeffer MA
    Circulation; 2005 Jun; 111(25):3411-9. PubMed ID: 15967846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
    J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM; Lokhnygina Y; Velazquez EJ; McMurray JJ; Leimberger JD; Lewis EF; Diaz R; Murin J; Pfeffer MA
    Am J Cardiol; 2009 Jul; 104(2):151-7. PubMed ID: 19576338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT).
    Shamshad F; Kenchaiah S; Finn PV; Soler-Soler J; McMurray JJ; Velazquez EJ; Maggioni AP; Califf RM; Swedberg K; Kober L; Belenkov Y; Varshavsky S; Pfeffer MA; Solomon SD;
    Am Heart J; 2010 Jul; 160(1):145-51. PubMed ID: 20598985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    Reed SD; Radeva JI; Weinfurt KP; McMurray JJ; Pfeffer MA; Velazquez EJ; Allsbrook JS; Masselink LE; Sellers MA; Califf RM; Schulman KA;
    Am Heart J; 2005 Aug; 150(2):323-9. PubMed ID: 16086938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality.
    Thomas KL; Al-Khatib SM; Lokhnygina Y; Solomon SD; Kober L; McMurray JJ; Califf RM; Velazquez EJ
    Am Heart J; 2008 Jan; 155(1):87-93. PubMed ID: 18082495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction.
    Murcia AM; Hennekens CH; Lamas GA; Jiménez-Navarro M; Rouleau JL; Flaker GC; Goldman S; Skali H; Braunwald E; Pfeffer MA
    Arch Intern Med; 2004 Nov; 164(20):2273-9. PubMed ID: 15534166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction.
    Thune JJ; Signorovitch JE; Kober L; McMurray JJ; Swedberg K; Rouleau J; Maggioni A; Velazquez E; Califf R; Pfeffer MA; Solomon SD
    Eur J Heart Fail; 2011 Feb; 13(2):148-53. PubMed ID: 21037250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial.
    Moukarbel GV; Signorovitch JE; Pfeffer MA; McMurray JJ; White HD; Maggioni AP; Velazquez EJ; Califf RM; Scheiman JM; Solomon SD
    Eur Heart J; 2009 Sep; 30(18):2226-32. PubMed ID: 19556260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heart attack patients with complications. Treat with valsartan, captopril, or both?
    Nguyen A; Sharma S
    Can Fam Physician; 2004 Aug; 50():1093-5. PubMed ID: 15455807
    [No Abstract]   [Full Text] [Related]  

  • 14. Valsartan an alternative to ACE inhibitor in high-risk MI.
    Geriatrics; 2004 Jan; 59(1):45. PubMed ID: 14755870
    [No Abstract]   [Full Text] [Related]  

  • 15. [When after myocardial infarction a pump weakness remains. ACE inhibitors and AT-1 blockers equivalent].
    MMW Fortschr Med; 2003 Dec; 145(49):18-9. PubMed ID: 14963986
    [No Abstract]   [Full Text] [Related]  

  • 16. An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry.
    Velazquez EJ; Francis GS; Armstrong PW; Aylward PE; Diaz R; O'Connor CM; White HD; Henis M; Rittenhouse LM; Kilaru R; van Gilst W; Ertl G; Maggioni AP; Spac J; Weaver WD; Rouleau JL; McMurray JJ; Pfeffer MA; Califf RM;
    Eur Heart J; 2004 Nov; 25(21):1911-9. PubMed ID: 15522470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT).
    Berry C; Pieper KS; White HD; Solomon SD; Van de Werf F; Velazquez EJ; Maggioni AP; Califf RM; Pfeffer MA; McMurray JJ
    Eur Heart J; 2009 Jun; 30(12):1450-6. PubMed ID: 19346225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context.
    Velazquez EJ; Pfeffer MA; McMurray JV; Maggioni AP; Rouleau JL; Van de Werf F; Kober L; White HD; Swedberg K; Leimberger JD; Gallo P; Sellers MA; Edwards S; Henis M; Califf RM;
    Eur J Heart Fail; 2003 Aug; 5(4):537-44. PubMed ID: 12921816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design.
    Pfeffer MA; McMurray J; Leizorovicz A; Maggioni AP; Rouleau JL; Van De Werf F; Henis M; Neuhart E; Gallo P; Edwards S; Sellers MA; Velazquez E; Califf R
    Am Heart J; 2000 Nov; 140(5):727-50. PubMed ID: 11054617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction).
    Lewis EF; Li Y; Pfeffer MA; Solomon SD; Weinfurt KP; Velazquez EJ; Califf RM; Rouleau JL; Kober L; White HD; Schulman KA; Reed SD
    JACC Heart Fail; 2014 Apr; 2(2):159-65. PubMed ID: 24720924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.